PMID- 34280026
OWN - NLM
STAT- MEDLINE
DCOM- 20210802
LR  - 20221207
IS  - 1557-7465 (Electronic)
IS  - 1079-9907 (Linking)
VI  - 41
IP  - 7
DP  - 2021 Jul
TI  - Quantitative Insight into Immunopathology of SARS-CoV-2 Infection.
PG  - 244-257
LID - 10.1089/jir.2020.0156 [doi]
AB  - Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV-2), which initiated as an 
      endemic from China, converted into a pandemic disease worldwide within a couple 
      of months' time. This has led researchers from all over the world to come 
      together to find and develop possible curative or preventive strategies, 
      including vaccine development, drug repurposing, plasma therapy, drug discovery, 
      and cytokine-based therapies. Herein, we are providing, a summarized overview of 
      immunopathology of the SARS-CoV-2 along with various therapeutic strategies 
      undertaken to COVID-19 with a vision for their possible outcome. High levels of 
      proinflammatory cytokines such as interleukin (IL)-7, G-CSF, IP-10, TNF-alpha, 
      monocyte chemoattractant protein-1 (MCP-1), and IL-2 in severe cases of COVID-19 
      have been observed. Immune responses play significant roles in the determination 
      of SARS-CoV-2 pathogenesis. Thus, exploring the underlying mechanism of the 
      immune system response to SARS-CoV-2 infection would help in the prediction of 
      disease course and selection of intensive care and therapeutic strategy. As an 
      effort toward developing possible therapeutics for COVID-19, we highlighted 
      different types of vaccines, which are under clinical trials, and also discussed 
      the impact of genome variability on efficacy of vaccine under development.
FAU - Soni, Bhavnita
AU  - Soni B
AD  - National Centre for Cell Science, Pune, India.
FAU - Kabra, Ritika
AU  - Kabra R
AD  - National Centre for Cell Science, Pune, India.
FAU - Singh, Shailza
AU  - Singh S
AUID- ORCID: 0000-0003-3817-8819
AD  - National Centre for Cell Science, Pune, India.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - J Interferon Cytokine Res
JT  - Journal of interferon & cytokine research : the official journal of the 
      International Society for Interferon and Cytokine Research
JID - 9507088
RN  - 0 (COVID-19 Vaccines)
SB  - IM
MH  - COVID-19/epidemiology/*immunology
MH  - COVID-19 Vaccines/*immunology/therapeutic use
MH  - Communicable Disease Control/methods/statistics & numerical data
MH  - Global Health/statistics & numerical data
MH  - Humans
MH  - Immune System/drug effects/*immunology
MH  - Immunity, Innate/drug effects/*immunology
MH  - Mutation
MH  - Pandemics/prevention & control
MH  - SARS-CoV-2/drug effects/genetics/*immunology
MH  - COVID-19 Drug Treatment
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-CoV-2
OT  - complement system
OT  - cytokine storm
OT  - immunopathology
OT  - vaccine development
EDAT- 2021/07/20 06:00
MHDA- 2021/08/03 06:00
CRDT- 2021/07/19 17:11
PHST- 2021/07/19 17:11 [entrez]
PHST- 2021/07/20 06:00 [pubmed]
PHST- 2021/08/03 06:00 [medline]
AID - 10.1089/jir.2020.0156 [doi]
PST - ppublish
SO  - J Interferon Cytokine Res. 2021 Jul;41(7):244-257. doi: 10.1089/jir.2020.0156.